Preserve Access to Affordable Generics and Biosimilars Act
Latest action · Sep 29, 2021 Ordered to be Reported in the Nature of a Substitute by the Yeas and Nays: 28 - 13.
Progress
Where this bill reached, and when. A stage with no date was not reached; one that failed a vote and later carried shows the date it carried.
- IntroducedApr 28, 2021
- Passed HouseNot reached
- Passed SenateNot reached
- To the PresidentNot reached
- Became lawNot reached
Summary
Preserve Access to Affordable Generics and Biosimilars Act
This bill authorizes the Federal Trade Commission (FTC) to initiate proceedings against parties to any agreement resolving or settling a patent infringement claim in connection with the sale of a drug or biological product. Such an agreement is presumed to have anticompetitive effects and is a violation of this bill if the filer of the generic drug or biosimilar application receives anything of value and agrees to limit or forego research, development, manufacturing, marketing, or sales of the generic drug or biosimilar.
An agreement is exempted if the only consideration granted to the generic manufacturer is (1) the right to market its product prior to the expiration of any statutory exclusivity, (2) a payment for reasonable litigation expenses, or (3) a covenant not to sue on any claim that the generic drug or biosimilar infringes a patent. An agreement is also exempt if the agreement's pro-competitive benefits outweigh the anticompetitive effects.
When a generic or biosimilar drug manufacturer enters into an agreement with another drug manufacturer related to the manufacturing, marketing, or sale of a drug, the manufacturers must certify that the material they have given the FTC concerning the agreement contains the complete agreement and any agreements related to that main agreement, including descriptions of any oral agreements or representations.
The bill imposes penalties for violations of this bill, including the forfeiture of the 180-day marketing exclusivity period for a generic drug.
Cosponsors 7
Members who signed on, in the order they did. Signatures ran from Apr 28, 2021 to Sep 28, 2021; 3 are original cosponsors, there from the day it was introduced.
| Seat | Cosponsor | Signed on | |
|---|---|---|---|
| D-NY | Carolyn B. Maloney | Original | Apr 28, 2021 |
| D-RI | David N. Cicilline | Original | Apr 28, 2021 |
| R-CO | Ken Buck | Original | Apr 28, 2021 |
| R-UT | Burgess Owens | May 28, 2021 | |
| D-DC | Eleanor Holmes Norton | Jul 20, 2021 | |
| R-NC | Ted Budd | Sep 24, 2021 | |
| D-TX | Sheila Jackson Lee | Sep 28, 2021 |
Committees 2
Where it was sent and what each committee and subcommittee did with it, in order.
| Chamber | Committee | What it did |
|---|---|---|
| House | Judiciary Committee | Referred Apr 28, 2021Markup Sep 29, 2021 |
| House | Energy and Commerce Committee | Referred Apr 28, 2021 |
| Health Subcommittee | Referred Apr 29, 2021 |
Actions 5
Everything that happened, newest first.
- Sep 29, 2021Committee Consideration and Mark-up Session Held.
- Sep 29, 2021Ordered to be Reported in the Nature of a Substitute by the Yeas and Nays: 28 - 13.
- Apr 29, 2021Referred to the Subcommittee on Health.
- Apr 28, 2021Introduced in House
- Apr 28, 2021Referred to the Committee on the Judiciary, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Research
What has been written about this bill: committee reports, cost estimates, the sponsor’s authority statement, printed hearings and the Congressional Research Service’s work.
Congressional Budget Office cost estimate
- Aug 11, 2022Estimated Budgetary Effects of H.R. 2891, the Preserve Access to Affordable Generics and Biosimilars ActAs ordered reported by the House Committee on the Judiciary on September 29, 2021
Constitutional authority
The sponsor’s statement, as printed in the Congressional Record, vol. 167, no. 73, April 28, 2021, page H2128.
Related bills 4
Companion bills and other measures the record links to this one.
| Bill | Title | Relationship | Latest action |
|---|---|---|---|
| S 1428 | Preserve Access to Affordable Generics and Biosimilars Act | Related bill | Dec 9, 2021 |
| HR 2375 | Preserve Access to Affordable Generics and Biosimilars Act | Reintroduction of | Dec 24, 2020 |
| HR 5237 | Reduced Costs and Continued Cures Act of 2021 | Related bill | Nov 1, 2022 |
| HR 5260 | Reduced Costs and Continued Cures Act | Related bill | Nov 1, 2022 |
Titles 2
Every title it has carried, official and short, at each stage.
- Official Title as Introduced
- To prohibit prescription drug companies from compensating other prescription drug companies to delay the entry of a generic drug, biosimilar biological product, or interchangeable biological product into the market.
- Short Title(s) as Introduced
- Preserve Access to Affordable Generics and Biosimilars Act
Subjects
Assigned by the Library of Congress. Policy area: Health.
Text 1
Each version as it was printed, newest first.
- Apr 28, 2021Introduced in House
Support LegiList
This page is free, carries no paywall, and is built and maintained by one person. If the record here is useful to you, a few dollars keeps it going.
Everything here is as published by Congress: the summary is the Congressional Research Service's, the action wording is the clerks', and the subjects are the Library of Congress's. How far it got is read from the actions themselves, taking the most recent one of each kind, so a bill that failed a vote and later passed is shown as having passed. Records come from this bill on Congress.gov and govinfo.gov; cost estimates are the Congressional Budget Office's, and the hearings are the printed hearings GovInfo publishes, which can appear months after the hearing.